First-Pass and Equilibrium Phase MRA Following Intravenous Bolus Injection of SH U 555 C

Tombach, Bernd; Reimer, Peter; Mahler, Marianne; Ebert, Wolfgang; Pering, Christiane; Heindel, Walter

doi:10.1016/s1076-6332(03)80251-9

Cited by 23 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7,17 Small-sized SPIOs are acquired by size screening, which is costly and low productive. 18 Alternatively, thermal decomposition of an appropriate iron precursor (e.g. iron oleate, iron acetylacetonate and dicyclopentadienyl iron) in high boiling nonpolar solvents has been demonstrated to be an effective method to produce SPIOs with great monodispersity, high crystallinity and tunable sizes, [19][20][21][22] and this procedure can also be scaled up.…”

Section: Introductionmentioning

confidence: 99%

Ultra-large-scale production of ultrasmall superparamagnetic iron oxide nanoparticles for T₁-weighted MRI

Rui

Liang

et al. 2016

RSC Adv.

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Ultra-large-scale production of ultrasmall superparamagnetic iron oxide nanoparticles for T₁-weighted MRI

Rui

Liang

et al. 2016

RSC Adv.

View full text Add to dashboard Cite

show abstract

“…factors for arterial vascular disease [78]. Placebo-controlled, double-blind studies at doses of 5, 10, 20, 40, and 80 µmol Fe/kg per body weight were conducted.…”

Section: Blood Pool Contrast Agentsmentioning

confidence: 99%

“…The most advanced agents with a filed FDA application is gadofosveset trisodium (EPIX Medical, Cambridge, USA; Schering, Berlin, Germany), formerly identified with the code name MS-325 [74,75]. The second agent, SH U 555 C (Schering, Berlin, Germany), an ultrasmall iron oxide, is derived from Ferucarbotran [76][77][78][79][80].…”

Section: Blood Pool Contrast Agentsmentioning

confidence: 99%

Soluble Paramagnetic Chelates and Stabilized Colloidal Particle Solutions of Iron Oxides as Contrast Agents for Magnetic Resonance Imaging

Tombach¹,

Reimer

2005

CMC

Self Cite

View full text Add to dashboard Cite

The development of contrast agents shortening the relaxation times of protons began more than 20 years ago in order to improve the capability of diagnosing disease by means of magnetic resonance imaging (MRI). A variety of extracellular and tissue specific contrast agents were developed based on two types of molecules. One type was related to soluble paramagnetic chelates and the other type to stabilized colloidal particle solutions of iron oxides. The chelate or metal complex of gadopentetate dimeglumine was the pioneering magnetic resonance (MR) contrast agent used in 1988. Chemical modifications of this chelate and the design of new chelates led to tissue or blood pool specificity in MRI. Similarly, modifications in coating materials and variations in size of iron oxide particles allowed for tissue specificity or blood pool properties in MRI. Both types of contrast agents offer excellent perspectives for clinical MRI and for molecular imaging.

show abstract

Superparamagnetic iron oxide particles: contrast media for magnetic resonance imaging

Lawaczeck¹,

Menzel

Pietsch³

2004

Applied Organom Chemis

111

View full text Add to dashboard Cite

The mainstream magnetic iron oxide particles used as contrast media for magnetic resonance (MR) imaging are composed of a magnetic iron oxide core surrounded by a dextran or carboxydextran coat. The core size ranges from 2 nm to less than 10 nm, and the hydrodynamic diameter ranges from 20 nm to about 120 nm. The coat prevents aggregation and sedimentation of the particles in aqueous solutions, achieves high biological tolerance, and prevents toxic side effects.Two kinds of particles are considered: (i) large particles (>30 nm), called superparamagnetic iron oxide particles (SPIOs) for liver imaging; (ii) smaller particles (<30 nm hydrodynamic diameter), called ultrasmall SPIOs (USPIOs), e.g. for MR angiography.To characterize the particles, Mössbauer spectra are presented for the two particle ensembles. These spectra allow insight into the magnetic coupling, the valency of the iron ions and a rough estimate of the core size to be deduced. On the basis of the concentration dependence of the MR signal intensities, two applications are discussed together with two representative clinical examples.Future indications for MR diagnostics, e.g. the labeling and tracking of stem cells during stem-cell therapy control, are outlined.

show abstract

First-Pass and Equilibrium Phase MRA Following Intravenous Bolus Injection of SH U 555 C

Cited by 23 publications

References 9 publications

Ultra-large-scale production of ultrasmall superparamagnetic iron oxide nanoparticles for T₁-weighted MRI

Ultra-large-scale production of ultrasmall superparamagnetic iron oxide nanoparticles for T₁-weighted MRI

Soluble Paramagnetic Chelates and Stabilized Colloidal Particle Solutions of Iron Oxides as Contrast Agents for Magnetic Resonance Imaging

Superparamagnetic iron oxide particles: contrast media for magnetic resonance imaging

Contact Info

Product

Resources

About

First-Pass and Equilibrium Phase MRA Following Intravenous Bolus Injection of SH U 555 C

Cited by 23 publications

References 9 publications

Ultra-large-scale production of ultrasmall superparamagnetic iron oxide nanoparticles for T1-weighted MRI

Ultra-large-scale production of ultrasmall superparamagnetic iron oxide nanoparticles for T1-weighted MRI

Soluble Paramagnetic Chelates and Stabilized Colloidal Particle Solutions of Iron Oxides as Contrast Agents for Magnetic Resonance Imaging

Superparamagnetic iron oxide particles: contrast media for magnetic resonance imaging

Contact Info

Product

Resources

About

Ultra-large-scale production of ultrasmall superparamagnetic iron oxide nanoparticles for T₁-weighted MRI

Ultra-large-scale production of ultrasmall superparamagnetic iron oxide nanoparticles for T₁-weighted MRI